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Abstract
Background: Traditional Chinese medicine (TCM) has been widely applied for cancer care in China. There have been a large
number of controlled clinical studies published in Chinese literature, yet no systematic searching and analysis has been
done. This study summarizes the current evidence of controlled clinical studies of TCM for cancer.
Methods: We searched all the controlled clinical studies of TCM therapies for all kinds of cancers published in Chinese in
four main Chinese electronic databases from their inception to November 2011. We bibliometrically analyzed the included
studies and assessed the reporting quality.
Results: A total of 2964 reports (involving 253,434 cancer patients) including 2385 randomized controlled trials and 579
non-randomized controlled studies were included. The top seven cancer types treated were lung cancer, liver cancer,
stomach cancer, breast cancer, esophagus cancer, colorectal cancer and nasopharyngeal cancer by both study numbers and
case numbers. The majority of studies (72%) applied TCM therapy combined with conventional treatment, whilst fewer
(28%) applied only TCM therapy in the experimental groups. Herbal medicine was the most frequently applied TCM therapy
(2677 studies, 90.32%). The most frequently reported outcome was clinical symptom improvement (1667 studies, 56.24%)
followed by biomarker indices (1270 studies, 42.85%), quality of life (1129 studies, 38.09%), chemo/radiotherapy induced
side effects (1094 studies, 36.91%), tumor size (869 studies, 29.32%) and safety (547 studies, 18.45%). Completeness and
adequacy of reporting appeared to improve with time.
Conclusions: Data from controlled clinical studies of TCM therapies in cancer treatment is substantial, and different
therapies are applied either as monotherapy or in combination with conventional medicine. Reporting of controlled clinical
studies should be improved based on the CONSORT and TREND Statements in future. Further studies should address the
most frequently used TCM therapy for common cancers and outcome measures should address survival, relapse/metastasis
and quality of life.
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Introduction
With an ageing worldwide population coupled with unhealthy
lifestyles and increased medical intervention, the burden of disease
and overall mortality has shifted gradually to primarily non-
communicable diseases such as cardiovascular disease and cancer
[1]. It is estimated that about 12.7 million cancer cases and 7.6
million cancer deaths occurred in 2008 [2], and the World Health
Organization (WHO) estimates that 84 million people would die of
cancer between 2005 and 2015 [3].
The earliest records of tumors can be traced back to inscriptions
on bones and tortoiseshells in the 16th–11th century B.C., and the
‘‘malignant sores’’ with ‘‘swelling but without ulceration’’ recorded
by traditional Chinese medicine (TCM) doctors in Qin Dynasty
(221-207 B.C.) already presented various theories and approaches
to treat cancer. [4].
TCM has increasingly become popular in the West including in
cancer patients [5]. Chinese medicine plays an important role in
minimizing disability, protecting cancer patients against suffering
from complications, and helping patients to live well [6]. Chinese
medicine may also assist in supportive and palliative care by
reducing side-effects of conventional treatment or improving
quality of life [7]. It is estimated the United States National Cancer
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Institute (NCI) spends around $120 million each year on CAM
related research projects [8].
A recent review of surveys of complementary and alternative
medicine use for cancer [9] identified 74 studies over the last 15
years, with 70% of publications occurring after 2005.
Previous reviews of TCM for cancer care in Chinese
publications have identified 716 case reports involving 1,198
patients [10], and 1,217 case series reports involving 92,945
patients [11], which showed a large prevalence of a diversity of
TCM clinical application for cancer patients. However, controlled
clinical studies were not included in these two reviews. In order to
catch a more comprehensive picture on TCM clinical usage for
cancer care in China, we systematically reviewed Chinese
literature to summarize the clinical evidence of controlled clinical
studies in this area.
Materials and Methods
Literature Search
We searched four major Chinese electronic databases including
China National Knowledge Infrastructure (CNKI) (1911-Novem-
ber 2011), Chinese Scientific Journal Database (VIP) (1989-
November 2011), Chinese BioMedical Literature Database (CBM)
(1978-November 2011), and Wanfang Database (1994-November
2011).
The Chinese searching terms were zhong yi (Chinese medicine),
zhong yao (Chinese medicine/Chinese herbal medicine), zhong yi
yao (Chinese medicine), zhong cheng yao (Chinese proprietary
medicine), zhen (needling/acupuncture), jiu (moxibustion), tui na
(tui na/massage), gua sha (scraping), ba guan (cupping), xue wei
(acupoint), qi gong, min zu yao (ethnomedicine), min jian (folk);
terms related to cancer disease including ai (cancer), liu (tumor), e
(malignant), bai xue (leukemia), gu sui (bone marrow) and lin ba
(lymph). Based on pilot searches, we noted improved outcomes by
searching for any match with study citation, abstract, keyword or
subject word.
Study Selection
Randomized controlled trials (RCT) or non-randomized
(clinical) clinical studies (CCS) with at least one group involving
TCM treatment for all types of cancer-related patients including
malignant tumor, malignant hematologic disease and patients with
precancerous condition were included. Controlled studies report-
ing ‘‘random allocation’’ were regarded as RCT, while controlled
studies without mentioning randomization were regarded as CCS,
including non-randomized controlled clinical trial (CCT) and
prospective/retrospective observational study.
Two authors (XL and GYY) screened the titles and abstracts of
the hits from literature searching, and full papers were retrieved by
downloading electronic versions (JC, JLY, XYZ, and YG) and
hand searching when electronic versions were unavailable (GYY).
Data Extraction
A structured data extraction form was designed (XL and XXL),
and 10 authors (YZ, GYY, JLY, YG, XXS, XYZ, JC, XXL, YX
and XL) participated in data extraction. The data extraction
involved study information as followed:
We extracted bibliometric information, including citation
information, publication types and funding information if avail-
able.
Clinical related indices consisted: 1) Disease and diagnosis: we
recorded the cancer types according to International Statistical
Classification of Diseases and Related Health Problems 10th
Revision [12]. We extracted clinical-related conditions which the
study addressed as the primary diagnosis of the included patients
in the studies. Studies about prevention were specially categorized.
Studies reported primary diagnosis related to TCM syndrome
differentiation were specially recorded. We recorded the reporting
completeness of diagnostic criteria, syndrome differentiation
(bianzheng) and application of diagnostic gold standard (patho-
logical diagnosis or cytological diagnosis). 2) Treatment and
control: We distinguished conventional treatments and TCM,
administration routes of TCM information both in treatment
group and control group, further classification of herbal medicine
and acupoint stimulation, and the reporting of treatment method,
dosage and treatment duration for both TCM and conventional
medicine. 3) Outcome measures: We extracted and classified
clinical-related outcomes. If quality of life was reported, the tool
for measuring was extracted if available. If the authors defined the
graded effectiveness by combining a number of outcomes, for
example, obvious improvement of quality of life and obvious
reduction of tumor size meant ‘‘very effective’’ while obvious
improvement of quality of life or obvious reduction of tumor size
meant ‘‘effective’’, rather than reporting each original outcome,
we recorded this as ‘‘combined outcome’’. Whether the author
recommended the clinical application as the study report
conclusion was also extracted.
We assessed the completeness of reporting according to
CONSORT Statement [13] for RCTs and TREND Statement
[14] for CCSs. We assessed the reporting of diagnosis criteria,
inclusion/exclusion criteria, allocation methods, blinding, details
of interventions and level of controls, and use of outcomes
measures for quality of life. We identified whether the study was
randomized and whether the method of randomization as
reported by authors. We identified blinding as either to patients,
physicians, evaluators and/or statisticians. If placebo was reported
and ‘‘double blind’’ was mentioned, we classified the blinding as
‘‘blinding to physicians and patients’’, while if placebo was
reported without mentioning the details of blinding, we classified
the blinding as ‘‘blinding to the patients’’.
We summarised well designed (reporting both randomization
methods and blinding details) studies reporting positive survival
outcomes to identify any significant evidence for the TCM
treatments.
All the extraction was verified by one author (XL), and any
discrepancies were discussed with the other authors for consensus.
Data Analysis
Data were presented by counts, percentage and frequency.
Epidata (Version 13.02) was applied for data extraction, and
Microsoft Excel and SPSS for Windows (version 17.0, Chicago,
Illinois, USA) were applied for data analysis (XL, XXL, GYY).
Results
Bibliometric Information
A total of 137,510 citations were identified and screened based
on searching in the four electronic databases, and 3737 full papers
were retrieved. A final 2,964 articles involving 253,434 (10-1700,
85.50670.59) participants were included after exclusion due to
duplication, non-controlled clinical studies, non-cancer related
studies or insufficient information (Figure 1).
A total of 2385 RCTs and 579 CCSs were identified. The
earliest controlled clinical study was a retrospective clinical report
about integrative medicine treating esophageal cancer published in
1984 [15]. The earliest RCTs we identified were one study of
herbal injection for cancer pain in 513 advanced-staged cancer
patients [16] and another study of herbal decoction for bone
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marrow and immune function-related side effects induced by
chemotherapy involving 40 patients [17], both of which were
published in 1985. The quantity of publications increased
especially after the year 2000. The publication types were further
divided into journal articles, dissertations and conference proceed-
ings. Studies reporting the funding information were specifically
summarised in order to present the quantity change tendency, too.
(Figure 2).
Participants and Diseases
Among the 2964 controlled clinical studies, 1490 studies focused
on the treatment of cancer, and the other studies focused on
precancerous condition, cancer-related clinical conditions, post-
surgery conditions and radio/chemotherapy induced side effects
(Table S2). Leucopenia was the most frequently reported primary
diagnosis in radio/chemotherapy-induced side effects (119 studies
out of 991), and cancer pain showed the highest frequency in
cancer-related conditions (123 studies out of 283).
Out of the total 2964 studies, 292 (9.85%) involving 26,585
(10.49%) patients focused on cancer or cancer-related conditions
prevention. Prevention of relapse and/or metastasis took up 16
studies out of 17 for relapse and/or metastasis, occupying the
largest percentage (94.12%) of prevention. There were also more
studies related to the prevention of radiation injury (61.19%), and
prevention of other drug induced side effects (60.00%) than the
studies about treatment of the same clinical conditions. (Table S1).
Cancer types were summarised into 17 categories according to
ICD-10 (Table S2, Figure 3). Calculating by case numbers and
study numbers, the highest prevalence cancer types treated,
included in descending order of priority, were respectively lung
cancer, liver cancer, stomach cancer, breast cancer, esophagus
cancer, colorectal cancer, and nasopharyngeal cancer (Figure 4).
Interventions in Different Groups
Among the total 2964 studies, the majority of 2770 (93.45%)
studies reported studies with 2 arms, 175 (5.90%) studies reported
3 arm studies, while 19 (0.64%) reported 4 or more arms in one
study.
Interventions in treatment groups involved purely TCM
intervention in 836 (28.21%) studies, while TCM combined with
conventional treatment in 2128 (71.79%) studies. The interven-
tions in control groups involved purely conventional treatment in
2570 (86.71%) studies, TCM combined with conventional
treatment in 204 (6.88%) studies, and purely TCM intervention
in 182 (6.14%) studies.
TCM intervention. TCM interventions reported in the total
2964 studies were classified into herbal medicine, acupoint
stimulation, dietary therapy, massage, TCM psychological in-
tervention, TCM five element music therapy and qigong. Herbal
medicine, including oral decoction, injection, external usage,
perfusion, aerosol inhalation, mouth rinsing and nasal feeding, was
the most frequently applied intervention in both treatment group
(2667 studies, 89.98%) and control group (327 studies, 11.03%).
Among all the types of herbal medicine, herbal medicine
decoction was the majority. More than half (1145 out of 1720,
66.57%) decoctions were individualized, and most of the studies
Figure 1. Flow chart of Literature searching and study selection. Presentation of the procedure of literature searching and study selection
with numbers of articles at each stage.
doi:10.1371/journal.pone.0060338.g001
Traditional Chinese Medicine in Cancer Care
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e60338
reported the detailed ingredients of the decoctions (Table 1). No
study reported quality assessment of herbs or final herbal products.
Out of 379 (12.79%) and 56 (1.89%) studies reporting acupoint
stimulation as the TCM treatment in treatment groups and
control groups respectively, needling acupuncture and acupoint
injection were dominating. Most of the studies related to acupoint
stimulation reported acupoint composition (treatment group 372
studies, 86.28%, control group 50 studies, 89.29%) (Table 1).
Conventional treatment. Conventional treatment reported
in the 2964 studies included chemotherapy, Western medicine as
routine treatment, radiotherapy, interventional therapy and
surgery. Chemotherapy was the dominating conventional treat-
ment in both treatment group (1170 studies, 54.98% in the 2128
studies reporting TCM+conventional medicine) and control group
(1328 studies, 47.87% in the 2774 studies reporting TCM+con-
Figure 2. Publication number of controlled clinical studies of TCM for cancer published in Chinese. Presentation of the number of
Chinese publication of controlled clinical studies of TCM for cancer in each year. The publication numbers of all the studies, journal articles,
conference proceedings, dissertations, and the publications reporting funding information are shown respectively.
doi:10.1371/journal.pone.0060338.g002
Figure 3. Cancer categories in controlled clinical studies of TCM for cancer published in China. Presentation of the categories of cancers
reported in the include studies according to ICD-10.
doi:10.1371/journal.pone.0060338.g003
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ventional medicine or conventional medicine only), followed by
western medicine or other routine treatments (Table 1).
Control types. There were 25 studies applied placebo and 2
applied sham acupuncture as the control, and another 6 studies
did not give any treatment to the patients in the control groups.
Detailed information of the intervention. Most studies
reported the details of treatment such as method description,
dosage and treatment duration. There were 410 (13.83%) studies
failed to present any treatment information for treatment group
and 376 (12.69%) for control group (Table 1).
Outcome Measurement
The most-frequently reported outcome measurement was
clinical symptom (1667 studies, 56.24%), followed by laboratory
indices (1270 studies, 42.85%), quality of life (1129 studies,
38.09%), chemo/radiotherapy induced side effects (1094,
36.91%), tumor size (869 studies, 29.32%) and safety (547 studies,
18.45%). Survival was reported in 433 (14.61%) studies while
metastasis and relapse were reported in 109 (3.68%) and 101
(3.41%). Among the total 1129 studies reporting quality of life as
the outcome measurement, Karnofsky Score was applied in most
of the studies (942 studies, 83.44%). There were 41 studies
reported quality of life measured by ‘‘QOL Score’’ without giving
any other detailed information, and we could not identify the exact
tool by any of the information provided by the publication and
references. (Table 2).
There were totally 516 studies (17.41%) reported clinical
effectiveness levels graded by several outcomes together without
giving adequate information for each of the original outcome.
(Table 2).
Overall Recommendation of Treatments
Among the total 2964 studies, 756 (25.51%) studies recom-
mended generalizing the treatment to the broader community
based on treatment effectiveness. Commonly seen recommenda-
tions included: ‘‘this treatment method is very effective with good
safety, and is very suitable for generalization in the clinical
applications’’.
Completeness of Reporting
Out of 2964 studies, 2136 (72.06%) reported diagnosis criteria
of the included patients, 2315 (78.10%) reported golden standard
for cancer diagnosis, such as pathological diagnosis or cytologic
diagnosis, 1020 (34.41%) reported inclusion and/or exclusion
criteria for the participants, while 1339 (45.18%) reported the
stages of cancer.
The reporting rates across different publication types were
different in diagnosis criteria, golden standard of cancer, in-
clusion/exclusion criteria, cancer staging and randomization
method. Dissertations more frequently reported all of the detailed
information mentioned above. (Table 3, Table 4).
Studies with funding information more frequently reported
inclusion/exclusion criteria, cancer staging and blinding details
than those without funding information. (Table 3, Table 4).
Reporting of inclusion/exclusion criteria, randomization meth-
od and details of blinding increased over time. (Figure 5).
There were 679 (22.91%) studies reported TCM diagnosis
based on syndrome differentiation as diagnosis standards as
selection criteria, reference for treatment or for outcome
measuring.
Randomization. Among the 2385 RCTs, 394 (16.52%)
reported adequate randomization methods, such as random table,
computer software randomization, drawing lots and throwing
coin. There were 33 studies reported ‘‘envelope method’’ or
‘‘random envelop ‘‘as the randomization method, and we counted
them as adequate randomization method, too. Conference
proceedings and dissertations had higher rate of reporting
randomization methods out of studies mentioning ‘‘randomiza-
tion’’ (Table 4).
Figure 4. Top 10 cancer types with study numbers. Presentation of the top 10 most frequently reported cancer types calculate by study
numbers. The numbers of participants ware also presented.
doi:10.1371/journal.pone.0060338.g004
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Blinding. A total of 63 studies reported blinding to the
participants, and 40 studies out of them (63.49%) reported the
people who were blinded, such as participants, physicians,
outcome measurers and statisticians. The other 23 studies just
mentioned ‘‘blinding’’, ‘‘single blinding’’ or ‘‘double blinding’’
without providing any further information. Again, conference
proceeding and dissertations reported the people who were
blinded more frequently if ‘‘blinding’’ was mentioned (Table 4).
Significant Evidence of TCM Treatments
There were five studies [18–22] reporting relatively well
designed RCTs with positive survival findings using Chinese
herbal medicine. One study used herbal extract granules, another
Table 1. Intervention and control for cancer patients in controlled clinical studies of TCM for cancer published in Chinese.
Therapy Treatment group % (/2964) Control group % (/2964)
Herbal medicine 2667 89.98% 327 11.03%
oral medication 2098 70.78% 273 9.21%
decoction (reporting ingredients) 1720 (1631) 58.03% 149 (131) 5.03%
individualized prescription (reporting ingredients) 1145 (1089) 38.63% 103 (90) 3.48%
proprietary herbal products (reporting ingredients) 758 (564) 25.57% 185 (111) 6.24%
hospital prepared herbal medicine (reporting ingredients) 303 (278) 10.22% 22 (19) 0.74%
injection 450 15.18% 51 1.72%
external 200 6.75% 15 0.51%
perfusion 15 0.51% 1 0.03%
aerosol inhalation 5 0.17% 0 0.00%
mouth rinsing 5 0.17% 1 0.03%
nasal feeding 1 0.03% 0 0.00%
Acupoint stimulation (acupoint composition) 379 (372) 12.79% 56 (50) 1.89%
needling 131 4.42% 22 0.74%
acupoint injection 122 4.12% 20 0.67%
moxibustion 71 2.40% 5 0.17%
electronic acupuncture 44 1.48% 3 0.10%
acupoint application 28 0.94% 3 0.10%
ear acupuncture 18 0.61% 1 0.03%
acupressure 16 0.54% 0 0.00%
laser or microwave stimulation 4 0.13% 2 0.07%
cupping 2 0.07% 0 0.00%
acupoint nerve stimulation 2 0.07% 0 0.00%
bee-sting therapy 2 0.07% 0 0.00%
point embedding therapy 1 0.03% 0 0.00%
sham acupuncture (control group) 2 0.07%
Other types of TCM intervention 31 1.05% 6 0.20%
dietary therapy 15 0.51% 2 0.07%
massage 10 0.34% 3 0.10%
TCM psychological intervention 3 0.10% 0 0.00%
TCM five element music therapy 2 0.07% 0 0.00%
qigong 1 0.03% 1 0.03%
Conventional medicine
chemotherapy 1170 39.47% 1328 44.80%
radiotherapy 354 11.94% 367 12.38%
western medicine or other routine treatment 622 20.99% 1228 41.43%
interventional therapy 162 5.47% 155 5.23%
surgery 73 2.46% 68 2.29%
Reporting completeness of interventions
no information about medication duration 410 13.83% 376 12.69%
no information about dosage 133 4.49% 190 6.41%
no information about medication 38 1.28% 114 3.85%
doi:10.1371/journal.pone.0060338.t001
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used a herbal capsule, and 3 used conventional Chinese herbal
decoctions. Two of the studies reported TCM alone as the
treatment intervention and the other 3 involved integrative TCM
and conventional medicine. (Table S3).
Discussion
This study systematically identified and analyzed controlled
clinical studies of TCM for cancer, and included 2964 studies from
1984 to 2011. This is the continuous part of previous reviews on
case reports and case series [10,11] with the same topic. Unlike
case reports and case series, Chinese publications of controlled
clinical studies of TCM for cancer did not commence until 1984.
This was consistent with the starting time of clinical trials in China,
as a previous searching found that the earliest clinical trial in
China started in the end of 1970s, and the first clinical trial in
TCM area was a study of Chinese herbal injection for angina
published in 1983 [23]. The number of publications increased
with time, especially after 2000, which paralleled significant
Table 2. Outcome measurements reported in controlled




clinical symptom 1667 56.24%
biomarker indices 1270 42.85%
quality of life 1129 38.09%
Karnofsky Score 942 31.78%
EORTC-QLQ 58 1.96%
QOL score without specific information 41 1.38%
FACT 27 0.91%




FLIC Scale 2 0.07%
GQLI (Gastrointestinal Quality of Life
Index)
2 0.07%
TCM quality of life scale 2 0.07%
other 15 0.51%
not reported 27 0.91%
chemo/radiotherapy induced side effects 1094 36.91%
tumor size 869 29.32%
safety 547 18.45%
survival 433 14.61%
post-surgery side effects 156 5.26%




imaging indexes 47 1.59%
fever 29 0.98%
depression indexes 10 0.34%
appetite 8 0.27%
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development of controlled clinical studies in China, and also
possibly of the establishment of Chinese medical databases.
Publication numbers fall in 2011 which may be partially due to
the time lag in recording of trials by the databases.
The most frequently reported cancer types were consistent with
the most common types of cancer (lung, stomach, liver, colon and
breast cancer) causing deaths each year according to WHO [24]
and basically consistent with the estimation of the new cancer
diagnosis for developing countries (lung & bronchus cancer,
stomach cancer, liver cancer, breast cancer and colon & rectum
cancer) [2] Leukemia was ranked 10th as calculated by patient
cases numbers, and was not ranked within the top 10 cancer types
if calculated by study numbers, which was quite different from case
series (5th rank) and case reports (2nd rank). One possibility is that
the treatment of leukemia is quite individualized, and there tends
to be more publications of case series and case reports where more
flexible and variable treatments are allowed than strict standard-
ized interventions expected in RCTs. Both clinical observations
and controlled clinical trials should be implemented to confirm the
effectiveness and safety in the future.
The clinical application of TCM is of high clinical interest not
only in the treatment of cancer and cancer related conditions, but
also in its prevention. We identified 292 studies involving 26,585
patients using TCM treatment for prevention of relapse/metas-
tasis of cancer or other cancer related conditions. Compared to
treatment interventions, TCM seems to have higher impact in the
prevention of relapse and/or metastasis, hemorrhage, radiother-
apy induced inflammation, radiation injury, chemo/radiotherapy
induced nausea and/or vomiting or other gastrointestinal disorder,
other chemotherapy included side effects, and other drug-induced
side effects. This is consistent with previously identified role of
TCM as complementary medicine adjuvant or postal to conven-
tional treatment [6–7,9].
In our literature search, whilst we did not apply any terms
directly related to precancerous lesions; we nevertheless identified
98 studies involving 11,759 patients with precancerous conditions.
A more comprehensive search with more precise search terms
including specific names of each precancerous condition should be
implemented for a complete view of studies of TCM in cancer
prevention.
Reporting completeness, including recording of inclusion/
exclusion criteria, randomization method for RCTs, and re-
cording of blinding improved with time. However, around half of
the studies still did not provide adequate information around
patient diagnosis and recruitment. This could be directly due to
the poor reporting of studies, or indeed that some of these studies
were actually retrospective clinical records summary instead of
prospective clinical trials although the published article claimed
itself as ‘‘clinical trial’’ or ‘‘clinical study’’. It is necessary and
essential for a prospective clinical study to recruit participants
based on pre-defined standardized diagnosis criteria and clear
selection criteria.
As far as the methodology is concerned, according to
CONSORT Statement [13], a randomized controlled trial must
report the details of randomization methods and blinding if
blinding was implemented, and for non-randomized clinical study,
TREND (Improving the Reporting Quality of Nonrandomized
Evaluations of Behavioral and Public Health Interventions)
Statement [14] requires that the authors report whether or not
participants, those administering the interventions, and those
assessing the outcomes were blinded to study condition assign-
ment. We recommend that future publications give detailed
information of randomization methods including sequence gener-
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including whether blinding is used and who are blinded if
available. If the report is based on existing previous data, the
article should clearly articulate that it is a retrospective report so as
todistinguish itself from prospective clinical studies.
If TCM syndrome differentiation is applied, the standard for
judgment should be clearly stated.
Quality of life as one of the most important clinical outcomes
and closely related to the patient wellbeing and increasingly
included in studies. However the tools for measuring quality of life
should have been more thoroughly reported with standard
references in order to ensure clearer contribution to clinical
decision making and design of further studies.
Funded studies, conference proceedings and dissertations
seemed to generate higher report quality, which indicates that
peer reviews is important for reporting of clinical studies, and the
researchers in China are aware and able to do better research,
however many of the Chinese journals haven’t paid enough
attention to the standard and strict requirement when accepting
submissions. It is urgently suggested that journals in China endorse
international standards such as CONSORT for randomized
controlled trials and TREND for non-randomized controlled
trials in their author guidelines to improve the quality of clinical
studies and reporting.
More than 20% of the studies failed to provide adequate gold
standard diagnosis for cancers, which could creates risks in
interpretation of data. As an essential element of cancer studies, we
suggest every clinical studyreport clear methods of cancer
diagnosis in the future. We searched the Chinese publications
based on general searching terms for example zhong yi (Chinese
medicine) and zhong yao (Chinese herbal medicine), publications
only labeled by the exact treatment such like the name of the
herbal formula would have been missed out. More standard
labelling is responsible for a more complete searching. We
recommend that the future publication have at least one label
related to Chinese medicine or herbal medicine for keyword or
subject word if the study is TCM-related.
It was difficult to judge whether papers were reports of
a prospective clinical studies without adequate information such
as randomization methods and inclusion/exclusion criteria. Thus
we combined together all clinical studies which involved compar-
ison between different groups of patients receiving different
interventions. Whilst most of studies mentioned ‘‘randomization’’,
we could not assess more than 2,000 studies for study type
(retrospective or prospective), and could not apply strict method-
ological evaluation as described in Cochrane Handbook [25].
Future studies should focus on specific types of TCM treatment for
certain cancer with more detailed evaluation and analysis to
ensure conclusions around effectiveness and safety and contribute
to evidence-based clinical recommendations.
With regards to reviews of case series and case reports of TCM
for cancer, individualized Chinese herbal medicine was the most
frequently reported intervention. We suggest that the future
studies focus on tailoring of treatment in cancer care.
Figure 5. Reporting completeness, randomization methods and blinding across years. Percentage of reporting diagnosis criteria,
inclusion/exclusion criteria, TCM diagnosis, golden standard of cancer, cancer staging, randomization method and blinding in the time order. Years
are presented by the clusters of 1984–1989, 1990–1999, 2000–2009 and 2010–2011.
doi:10.1371/journal.pone.0060338.g005
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Among the studies published in Chinese, herbal medicine is the
main TCM intervention for cancer, comprising almost 90% in the
total 2964 studies, which is also 7 times the number of
acupuncture studies. This difference is much larger compared to
a review based on English publications (acupuncture in 71 studies
while Chinese herbal medicine in 11 studies) [9], which might
reflect policy and levels of use of herbal medicine in different
countries as well as publication bias. Although most of the
included studies involved herbal medicine, there is no study
reporting quality assessment of herbs or herbal products. Since the
quality of herbal medicine is closely related to the clinical
effectiveness and safety, and also essential for the quality of
clinical study [26], this issue should be addressed in the future.
There have been a large number of controlled clinical studies of
TCM for cancer, especially certain types with higher frequency
such as lung cancer, liver cancer, stomach cancer, colorectal
cancer, breast cancer, esophagus cancer, nasopharyngeal cancer,
cervical cancer, ovarian cancer and pancreatic cancer. Systematic
reviews could be implemented in order to access the effectiveness
and safety of the TCM treatments for thesis types of cancers so
that higher quality of evidence could be brought about based on
the existing clinical information, the money and time have been
spent, for the contribution to the clinical practice. One literature
review of systematic reviews of TCM published in PubMed and
Cochrane Library during the year 1999 to 2009 [26] identified 4
systematic reviews of TCM for cancer care including nasopha-
ryngeal cancer, esophageal cancer, unrespectable hepatocellular
cancer, and cancer pain respectively. We also identified Cochrane
systematic reviews or protocols about Chinese herbal medicine for
certain types of cancer including gastric precancerous lesions [27],
Chinese herbal medicine for advanced pancreatic cancer [28],
Chinese herbal medicine for chemotherapy side effects in co-
lorectal cancer [29], Chinese herbal medicine for side effects of
breast cancer [30], and herbal medicine for advanced colorectal
cancer [31].
Conclusions
In future standard and adequate reporting of TCM cancer
studies is essential. More attention should be paid to reporting
clinical outcomes of importance to patient care and clinical
decision making including survival times, extent of relapse/
metastasis and quality of life.
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